Literature DB >> 1807367

The urine urokinase concentration in end stage renal disease with acquired renal cyst.

S Y Hong1, D H Yang, B H Lee, E K Ki, K H Chung.   

Abstract

To see whether there was any difference in the urine urokinase concentration between acquired cystic kidney disease (ACKD) group and control (non cyst) group in end stage renal disease patients (ESRD), we evaluated fifty ESRD patients who had been maintained on chronic hemodialysis for various period. The urine urokinase concentration was higher in the ACKD group (17.5 +/- 14.7 unit/ml, range 13.5-47.0 unit/ml, n = 9) than the control group (4.1 +/- 3.4 unit/ml, range 0.5-12.0 unit/ml, n = 36) (p less than 0.001), and polycyst group (2.6 +/- 1.8 unit/ml, range 1.0-5.1 unit/ml, n = 5) (p less than 0.01). But there was no difference between the control group and polycyst group. In the control group and the ACKD group, there was a direct relation between the dialysis duration and the urokinase concentration and the longer the dialysis duration, the higher the urine urokinase concentration (r squared = 0.424, p = 0.0001). The hemodialysis duration was longer in the ACKD group (42 +/- 17.0 months) than the control group (20.0 +/- 12.5 months) (p less than 0.005). These findings suggest that urokinase may be responsible for cystogenic degeneration in ESRD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1807367      PMCID: PMC4532122          DOI: 10.3904/kjim.1991.6.2.64

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  30 in total

1.  Source of increased plasminogen activators during pregnancy and puerperium.

Authors:  H Shimada; E Takashima; M Soma; M Murakami; Y Maeda; S Kasakura; A Takada; Y Takada
Journal:  Thromb Res       Date:  1989-04-15       Impact factor: 3.944

Review 2.  Renal cystic disease. Insights from recent experimental investigations.

Authors:  E D Avner
Journal:  Nephron       Date:  1988       Impact factor: 2.847

Review 3.  Thrombolytic therapy: current status (1).

Authors:  V J Marder; S Sherry
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

4.  Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators.

Authors:  C Kluft
Journal:  Thromb Haemost       Date:  1979-04-23       Impact factor: 5.249

5.  Urokinase excretion in patients with renal diseases.

Authors:  J Vreeken; J Boomgaard; K Deggeller
Journal:  Acta Med Scand       Date:  1966-08

6.  Acquired cystic disease of the end-stage kidney.

Authors:  J J Gehrig; T I Gottheiner; R S Swenson
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

7.  Characterization of a specific anti-human urokinase antibody: development of a sensitive competition radioimmunoassay for urokinase antigen.

Authors:  K Huber; J Kirchheimer; B R Binder
Journal:  J Lab Clin Med       Date:  1984-05

8.  Reversible changes of tubular cell and basement membrane in drug-induced renal cystic disease.

Authors:  Y S Kanwar; F A Carone
Journal:  Kidney Int       Date:  1984-07       Impact factor: 10.612

Review 9.  Polycystic kidney disease: a predominance of giant nephrons.

Authors:  J J Grantham
Journal:  Am J Physiol       Date:  1983-01

10.  Urinary plasminogen activator activity in progressive renal failure.

Authors:  S Y Hong; D H Yang
Journal:  Korean J Intern Med       Date:  1990-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.